FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.

ABSTRACT:

Background

Acute pancreatitis (AP) presents a significant clinical challenge with limited therapeutic options. The complex etiology and pathophysiology of AP emphasize the need for innovative treatments. This study explores mRNA-based therapies delivering fibroblast growth factor 21 (FGF21) and apolipoprotein A1 (APOA1), alone and in combination, for treating experimental AP.

Methods

Liver-targeted lipid nanoparticles (LNP)-mRNA formulations encoding FGF21, APOA1, and a chimeric APOA1-FGF21, were first tested for protein expression and bioavailability in vitro and in mice fed a high-fat diet. Efficacy studies were performed in the caerulein-induced AP (Cer-AP) model, and a new AP model combining ethanol feeding with ethanol binge plus palmitoleic acid administration, the EtO

SUBMITTER: Lopez-Pascual A 

PROVIDER: S-EPMC11773771 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature